Emergent Stock Financials

EBS
 Stock
  

USD 29.72  0.83  2.72%   

Emergent Biosolutions Earnings Before Interest Taxes and Depreciation Amortization EBITDA are relatively stable at the moment as compared to the past year. Emergent Biosolutions reported last year Earnings Before Interest Taxes and Depreciation Amortization EBITDA of 472.7 Million. As of 08/09/2022, Earnings before Tax is likely to grow to about 339.2 M, while Net Income Per Employee is likely to drop slightly above 83 K.
  
With this module, you can analyze Emergent financials for your investing period. You should be able to track the changes in Emergent Biosolutions individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.

Emergent Most Recent Estimates

Quarterly Earnings Growth YOY
0.022
EPS Estimate Next Quarter
0.4
Diluted Eps
1.65
EPS Estimate Current Year
1.54
EPS Estimate Next Year
2.33
EPS Estimate Current Quarter
0.37
Earnings Share
1.65

Revenues

1.93 Billion

Understanding current and past Emergent Biosolutions Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Emergent Biosolutions' financial statements are interrelated, with each one affecting the others. For example, an increase in Emergent Biosolutions' assets may result in an increase in income on the income statement.
The fundamental analysis of Emergent Biosolutions is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Emergent Biosolutions includes many different criteria found on its balance sheet. For example, investors should never minimize Emergent Biosolutions' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Emergent Biosolutions' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Emergent Biosolutions.

Emergent Biosolutions Cash

Chance Of Financial Distress
Less than 42
Emergent Biosolutions has less than 42 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Emergent Biosolutions stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Emergent Biosolutions' official financial statements usually reflect Emergent Biosolutions' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Emergent Biosolutions. For example, before you start analyzing numbers published by Emergent accountants, it's critical to develop an understanding of what Emergent Biosolutions' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Emergent Biosolutions' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Emergent Biosolutions' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Emergent Biosolutions' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Emergent Biosolutions. Please utilize our Beneish M Score to check the likelihood of Emergent Biosolutions' management to manipulate its earnings.

Emergent Biosolutions Company Summary

Emergent Biosolutions competes with Verizon Communications. Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats in the United States. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. Emergent Biosolutions operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 2416 people.
Specialization
Healthcare, Drug Manufacturers - Specialty & Generic
InstrumentUSA Stock View All
ExchangeNew York Stock Exchange
CIK Number0001367644
CUSIP29089Q105
Older SymbolEBS
RegionNorth America
LocationMaryland; U.S.A
Business Address400 Professional Drive,
SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic
BenchmarkDOW
Websitewww.emergentbiosolutions.com
Phone240 631 3200
CurrencyUSD - US Dollar
You should never invest in Emergent Biosolutions without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Emergent Stock, because this is throwing your money away. Analyzing the key information contained in Emergent Biosolutions' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Emergent Biosolutions Key Financial Ratios

Generally speaking, Emergent Biosolutions' financial ratios allow both analysts and investors to convert raw data from Emergent Biosolutions' financial statements into concise, actionable information that can be used to evaluate the performance of Emergent Biosolutions over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Emergent Biosolutions reports annually and quarterly.

Emergent Biosolutions Key Balance Sheet Accounts

201720182019202020212022 (projected)
Inventories142.81 M205.8 M222.5 M307 M350.8 M378.49 M
Receivables143.65 M262.5 M270.7 M230.9 M274.7 M296.39 M
Accounts Payable41.75 M80.7 M94.8 M136.1 M128.9 M139.08 M
Total Assets1.07 B2.23 B2.33 B2.88 B2.96 B2.41 B
Current Assets485.4 M620.8 M686.2 M1.2 B1.27 B1.01 B
Assets Non Current584.8 M1.61 B1.64 B1.69 B1.69 B1.39 B
Cash and Equivalents179.3 M112.4 M168 M621.5 M576.3 M460.31 M
Total Debt13.5 M794.6 M811.3 M874.8 M841 M668.18 M
Debt Non Current13.5 M784.5 M798.4 M841 M809.4 M645.33 M
Shareholders Equity912.3 M1.01 B1.09 B1.45 B1.62 B1.34 B
Inventory142.8 M205.8 M222.5 M307 M350.8 M378.49 M
Total Liabilities157.9 M1.22 B1.24 B1.44 B1.34 B1.07 B
Current Liabilities100.1 M200.4 M216.3 M384.5 M373.8 M403.31 M
Tax Assets17.86 M16.09 M5.2 M22 M19.8 M16.75 M

Emergent Biosolutions Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Emergent Biosolutions' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201720182019202020212022 (projected)
Direct Expenses195.71 M322.3 M433.5 M524 M757.5 M817.3 M
Consolidated Income82.6 M62.7 M54.5 M305.1 M230.9 M249.13 M
Cost of Revenue187.7 M322.3 M433.5 M524 M757.5 M817.3 M
Gross Profit373.2 M460.1 M672.5 M1.03 B1.04 B825.73 M
Interest Expense6.6 M9.9 M38.4 M31.3 M34.5 M27.36 M
Net Income82.6 M62.7 M54.5 M305.1 M230.9 M249.13 M
Operating Expenses248.9 M370.3 M558.4 M597.6 M682.6 M558.27 M
Operating Income124.3 M89.8 M114.1 M433.8 M352.6 M380.44 M
Revenues560.9 M782.4 M1.11 B1.56 B1.79 B1.93 B
Income Tax Expense36 M18.8 M22.9 M102.1 M83.5 M90.09 M

Emergent Biosolutions Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Emergent Biosolutions. It measures of how well Emergent is doing because it can show the actual money that comes into and out of the company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Emergent Biosolutions brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Emergent had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Emergent Biosolutions has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201720182019202020212022 (projected)
Capital Expenditure(54.8 M)(72.1 M)(86.9 M)(141 M)(225 M)(230.92 M)
Depreciation Amortization and Accretion42.6 M62.2 M110.7 M114.5 M123.8 M133.57 M
Net Cash Flow or Change in Cash and Cash Equivalents(93.2 M)(66.9 M)55.6 M453.5 M(45.2 M)(46.39 M)
Issuance Purchase of Equity Shares(13.8 M)15.8 M8.2 M31.6 M(90.1 M)(92.47 M)
Net Cash Flow from Financing(51.4 M)788.7 M(35.9 M)69.5 M(141 M)(144.71 M)
Net Cash Flow from Investing(249.9 M)(897.2 M)(96.9 M)(151 M)(225 M)(242.76 M)
Net Cash Flow from Operations208.1 M41.8 M188 M536 M321.1 M256.01 M
Share Based Compensation15.2 M23.2 M26.7 M51 M42.4 M45.75 M

Emergent Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Emergent Biosolutions's current stock value. Our valuation model uses many indicators to compare Emergent Biosolutions value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Emergent Biosolutions competition to find correlations between indicators driving Emergent Biosolutions's intrinsic value. More Info.
Emergent Biosolutions is one of the top stocks in cash and equivalents category among related companies. It is rated as one of the top companies in total debt category among related companies making up about  1.98  of Total Debt per Cash and Equivalents. Emergent Biosolutions Cash and Equivalents is relatively stable at the moment as compared to the past year. Emergent Biosolutions reported last year Cash and Equivalents of 576.3 Million. Comparative valuation analysis is a catch-all model that can be used if you cannot value Emergent Biosolutions by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Emergent Biosolutions' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Emergent Biosolutions' earnings, one of the primary drivers of an investment's value.

Emergent Biosolutions Systematic Risk

Emergent Biosolutions' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Emergent Biosolutions volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Emergent Biosolutions correlated with the market. If Beta is less than 0 Emergent Biosolutions generally moves in the opposite direction as compared to the market. If Emergent Biosolutions Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Emergent Biosolutions is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Emergent Biosolutions is generally in the same direction as the market. If Beta > 1 Emergent Biosolutions moves generally in the same direction as, but more than the movement of the benchmark.
.

About Emergent Biosolutions Financials

What exactly are Emergent Biosolutions Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Emergent Biosolutions' income statement, its balance sheet, and the statement of cash flows. Potential Emergent Biosolutions investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Emergent Biosolutions investors may use each financial statement separately, they are all related. The changes in Emergent Biosolutions's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Emergent Biosolutions's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines that you should keep in mind when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase year after year due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt to equity ratio because this number will tell you how much risk it has. If a company such as Emergent Biosolutions is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to try and figure out if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that net revenue of Emergent grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only grown by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Emergent Biosolutions Thematic Clasifications

Emergent Biosolutions is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
Pharmaceutical Products Idea
Pharmaceutical ProductsView
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas

Emergent Biosolutions August 9, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Emergent Biosolutions help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Emergent Biosolutions. We use our internally-developed statistical techniques to arrive at the intrinsic value of Emergent Biosolutions based on widely used predictive technical indicators. In general, we focus on analyzing Emergent Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Emergent Biosolutions's daily price indicators and compare them against related drivers.
Information Ratio(0.00449)
Maximum Drawdown23.42
Value At Risk(7.08)
Potential Upside7.19
Continue to Investing Opportunities. Note that the Emergent Biosolutions information on this page should be used as a complementary analysis to other Emergent Biosolutions' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Complementary Tools for Emergent Stock analysis

When running Emergent Biosolutions price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Is Emergent Biosolutions' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Emergent Biosolutions. If investors know Emergent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Emergent Biosolutions listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
0.022
Market Capitalization
1.5 B
Quarterly Revenue Growth YOY
-0.39
Return On Assets
0.049
Return On Equity
0.0631
The market value of Emergent Biosolutions is measured differently than its book value, which is the value of Emergent that is recorded on the company's balance sheet. Investors also form their own opinion of Emergent Biosolutions' value that differs from its market value or its book value, called intrinsic value, which is Emergent Biosolutions' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Emergent Biosolutions' market value can be influenced by many factors that don't directly affect Emergent Biosolutions' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Emergent Biosolutions' value and its price as these two are different measures arrived at by different means. Investors typically determine Emergent Biosolutions value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Emergent Biosolutions' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.